Search Within

Gabriella D'Andrea-Carlino

  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Meeting Abstract (13)
  2. Journal Article (4)
Groups
  1. Breast Medicine Service (17)
  2. Department of Medicine (17)
  3. GSK Faculty (17)
  4. Human Oncology and Pathogenesis Program (17)
  5. Solid Tumor Oncology Division (17)
  6. Survivorship Research (17)

More Groups

People
  1. Sarat Chandarlapaty (15)
  2. Clifford Hudis (14)
  3. Shanu Modi (14)
  4. Sujata Patil (13)
  5. Diana Lake (11)
  6. Maura Dickler (10)

More People

Years
  1. 2021 (1)
  2. 2018 (1)
  3. 2017 (2)
  4. 2016 (1)
  5. 2015 (3)
  6. 2014 (4)

More Years

Publications
  1. Cancer Research (6)
  2. Journal of Clinical Oncology (5)
  3. Annals of Oncology (1)
  4. Breast Cancer Research (1)
  5. Clinical Breast Cancer (1)
  6. Clinical Cancer Research (1)

More Publications

Publishers
  1. American Association for Cancer Research (7)
  2. American Society of Clinical Oncology (5)
  3. Biomed Central Ltd (2)
  4. Elsevier Inc. (2)
  5. Oxford University Press (1)

Results (17)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Toxicity of an Fc engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable anti-tumor immunity in patients
    Meeting Abstract

    Knorr, D.; Ravetch, J.; D'Andrea, G.; Vahdat, L.; Klebanoff, C.; Robson, M.
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Co-targeting ER and FGFR in patients with ER+/HER2- FGFR amplified (amp) metastatic breast cancer (MBC)
    Meeting Abstract

    Jhaveri, K.; Syed, U.; Wong, S.; D'Andrea, G.; Lake, D.; Goldfarb, S.; Gajria, D.; Ligresti, L.; Rogado, A.; Reis-Filho, J.; more...
    European Journal of Cancer (2018)

    Fulltext@MSK | Save
  • Oncologist use and perception of large panel next-generation tumor sequencing
    Journal Article

    Schram, A. M.; Reales, D.; Galle, J.; Cambria, R.; Durany, R.; Feldman, D.; Sherman, E.; Rosenberg, J.; D'Andrea, G.; Baxi, S.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer
    Journal Article

    Jhaveri, K.; Wang, R.; Teplinsky, E.; Chandarlapaty, S.; Solit, D.; Cadoo, K.; Speyer, J.; D'Andrea, G.; Adams, S.; Patil, S.; more...
    Breast Cancer Research (2017)

    Fulltext@MSK | Save
  • A phase I trial of ganetespib (heat shock protein 90 inhibitor) in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 positive (HER2+) metastatic breast cancer (MBC)
    Meeting Abstract

    Jhaveri, K.; Teplinsky, E.; Chandarlapaty, S.; Solit, D.; Cadoo, K.; Speyer, J.; D'Andrea, G.; Adams, S.; Patil, S.; Haque, S.; more...
    Cancer Research (2016)

    Fulltext@MSK | Save
  • Phase I study of PI3Kα inhibitor BYL719 + aromatase inhibitor (AI) in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Moynahan, M. E.; Modi, S.; Hamilton, N.; Caravella, B. A.; Zamora, S.; Dang, C.; Gilewski, T.; Traina, T.; Comen, E.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase I trial: PI3Kα inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Moynahan, M. E.; Modi, S.; Caravella, B. A.; Datko, F. M.; Zamora, S.; Comen, E.; Gilewski, T.; Sugarman, S. M.; D'Andrea, G.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • A phase I clinical trial of ganetespib (heat shock protein 90 inhibitor) in combination with paclitaxel and trastuzumab in human epidermal growth factor receptor-2 positive (HER2+) metastatic breast cancer
    Meeting Abstract

    Jhaveri, K.; Cadoo, K.; Chandarlapaty, S.; Teplinsky, E.; Speyer, J.; D'Andrea, G.; Patil, S.; Haque, S.; Friedman, K.; Heese, S.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase I trial of daily PI3K alpha inhibitor BYL719 plus letrozole (L) or exemestane (E) for patients (pts) with hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Modi, S.; Datko, F. M.; Moynahan, M. E.; Zamora, S.; D'Andrea, G.; Lake, D.; Goldfarb, S. B.; Patil, S.; Singh, S.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Monitoring PIK3CA mutant allele fraction (AF) in cell-free DNA (cfDNA) in metastatic breast cancer (MBC) patients treated with PI3K alpha-inhibitor plus letrozole (L) or exemestane (E)
    Meeting Abstract

    Moynahan, M. E.; Sung, P.; Asham, M.; Zamora, S.; Shah, P. D.; Modi, S.; Lake, D.; D'Andrea, G.; Goldfarb, S. B.; Chandarlapaty, S.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save